#biopharma

3개의 글

July 29, 2026

United Therapeutics (UTHR) Stock Outlook 2026: A PAH Cash Machine Carrying a Xenotransplant Lottery Ticket

United Therapeutics (UTHR) stock outlook for 2026. A qualitative deep dive into the treprostinil pulmonary hypertension franchise, Tyvaso DPI growth, Liquidia and sotatercept competition, patent-cliff risk, and the long-shot optionality of manufactured organs and xenotransplantation.

UTHR United Therapeutics pulmonary hypertension

17 de junio de 2026

INCY (Incyte) Pronóstico de Acciones 2026: El Acantilado de Patentes de Jakafi Frente a la Apuesta por el Pipeline

Análisis de INCY (Incyte Corporation) para 2026: cómo el acantilado de patentes de Jakafi (ruxolitinib) y el crecimiento de Opzelura definen la tesis de inversión en esta biopharma especializada en inhibidores JAK, con panorama de pipeline, competidores y escenarios de riesgo.

INCY Incyte biopharma

June 17, 2026

INCY (Incyte) Stock Forecast 2026: Patent Cliff vs. Pipeline — What Investors Need to Know

INCY Incyte stock forecast 2026: Jakafi ruxolitinib patent cliff, Opzelura atopic dermatitis vitiligo growth, JAK inhibitor competition from BMS and Pfizer, pipeline catalysts, and what biopharma investors must verify before buying.

INCY Incyte biopharma